Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden
Acta Oncol
.
2021 Jan;60(1):56-60.
doi: 10.1080/0284186X.2020.1847321.
Epub 2020 Dec 10.
Authors
Giuseppe Fallara
1
2
,
Ingela Franck Lissbrant
3
,
Johan Styrke
4
,
Francesco Montorsi
1
,
Rolf Gedeborg
5
,
Fredrik Sandin
6
,
Pär Stattin
2
Affiliations
1
Division of Experimental Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
2
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
3
Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden.
4
Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
5
Department of Surgical Sciences, Anaesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden.
6
Regional Cancer Centre, Uppsala/Örebro, Uppsala University Hospital, Uppsala, Sweden.
PMID:
33302761
DOI:
10.1080/0284186X.2020.1847321
No abstract available
Publication types
Letter
MeSH terms
Androstenes* / therapeutic use
Delivery of Health Care*
Humans
Registries
Sweden
Substances
Androstenes
abiraterone